Inovio Pharmaceuticals (INO) reported a narrower-than-expected loss for Q1 2026, with an EPS of -$0.28, beating the consensus estimate of -$0.44. This positive surprise of 36.36% did not prevent the stock from falling.
The company's shares dropped 3.55% immediately after the announcement and continued to decline, closing at $1.22, down 6.15% from the previous day's close. The one-week decline reached approximately 13.5%.
Inovio demonstrated strong financial discipline, reducing its per-share loss from $0.51 in Q1 2025 to $0.28. This improvement reflects effective cost management and support for the INO-3107 program.
However, cash reserves fell from $58.5 million at end-2025 to $37.7 million by end-Q1 2026, raising sustainability concerns. According to Bond.az, the company is burning cash quickly but maintains more cash than debt.
Analysts questioned the sustainability of Inovio's cash runway and the competitive landscape for INO-3107. The company projects an operational net cash burn of approximately $18 million for Q2 2026.
